Hormonal
Expanding access to GLP-1 and GIP/GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) for eligible populations in the US could avert approximately 43,719 deaths annually by reducing obesity-related mortality.
If you have a BMI of 30 or higher (or 27+ with conditions like diabetes), you are likely eligible for GLP-1 medications like semaglutide or tirzepatide. These drugs are highly effective for weight loss and can significantly reduce your risk of early death from obesity-related causes. The main barrier is not efficacy, but cost and insurance coverage. Discuss these options with your doctor and explore insurance coverage options or patient assistance programs, as expanded access policies may soon make these treatments more available and affordable.
if access were expanded to all eligible individuals, the number of lives saved could rise by 43,719 annually [95% UI: 43,679 – 43,759]
Why this rating
The study is a modeling projection based on existing clinical trial data and epidemiological hazard ratios, not a new randomized controlled trial of mortality outcomes.
Source
Estimating the lives that could be saved by expanded access to weight-loss drugs
Abhishek Pandey et al. · medRxiv · 2024
DOI 10.1101/2024.06.27.24309551
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →